Docetaxel and anti-androgens such as enzalutamide, apalutamide, darolutamide, and abiraterone, as monotherapy or in combination, are approved for the treatment of metastatic hormone sensitive PC; while, the therapeutic scenario of metastatic castration-resistant PC (mCRPC) has been considerably enriched by the introduction of abiraterone and enzalutamide, cabazitaxel, immuno-modulatory agent sipuleucel-T, radiopharmaceutical agents such as radium-223 (only in case of bone metastasis), and 177Lutetium-prostate-specific membrane antigen (PSMA)-617 [3]. This evidence concerns the gene FOLH1 and bone metastasis.